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Background
Hypersensitivity reactions (HR) to chemotherapy agents
are increasingly frequent and lead to the discontinuation
of potentially curative drugs. Rapid drug desensitization
(RDD) is the only strategy that protects from anaphylaxis,
while providing first line treatment options. The safety
and efficacy of RDD depends on the outcomes of large
series of desensitized patients. We present the outcomes
data for platins and taxanes from the Desensitization
Unit of the Immunoallergology Department in Lisbon’s
Santa Maria Hospital.
Methods
A retrospective review between July 2008 and December
2013 was done. All patients with HR to platins and tax-
anes who were desensitized were included. The Brigham
and Women’s Hospital’s desensitization protocol with 3
bags (1:100, 1:10 and 1:1 of the final target concentration)
and 12 consecutive steps was used (5.8 hours total infusion
time). Frequency and severity of breakthrough reactions
during the desensitization procedures were analyzed.
Results
135 patients were desensitized to 140 drugs (5 double
desensitizations), with a total of 609 desensitizations. The
drugs included platins (carboplatin=32; oxaliplatin=40;
cisplatin=3) and taxanes (docetaxel=38; paclitaxel=27),
with a mean of desensitization per patient of 4.6 for pla-
tins and 4.1 for taxanes. During desensitization, 77
(12.6%) HR occurred in 49 patients (mild=59; moder-
ate=13; severe=5) of which 64 (83%) were induced by pla-
tins. All breakthrough HR in the taxanes group occurred
during the 1st (9-69%) and 2nd (4-31%) desensitizations.
Platin-sensitized patients reacted not only during the 1st
(27-42%) and 2nd (18-28%), but also on the 3rd (5-7.8%),
4th (5-7.8%) and other (9-14.4%) desensitizations. Most
HR occurred on the last step of the protocol (53-69%).
Only one patient did not receive the target dose due to
recurrent anaphylaxis.
Conclusions
97% of this large cohort of platin and taxane hypersensi-
tive patients were able to receive their target dose through
the 3 bag, 12-steps protocol with mild or no HR, confirm-
ing the efficacy and safety of protocol. Platin-sensitized
patients react in multiple desensitizations, supporting the
need for repeated desensitization at each exposure. Inter-
estingly taxane desensitizations induced fewer reactions,
which were limited to the first 2 desensitizations. Future
studies are needed to assess the safety of shorter protocols
after the first 2 desensitizations to taxanes.
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